Comparative Pharmacology
Head-to-head clinical analysis: COXANTO versus NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COXANTO versus NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE.
COXANTO vs NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inhibitor of soluble epoxide hydrolase (sEH), increasing levels of epoxyeicosatrienoic acids (EETs), which have vasodilatory, anti-inflammatory, and antifibrotic effects.
Naproxen sodium is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, which mediates inflammation, pain, and fever. Diphenhydramine hydrochloride is a first-generation antihistamine that antagonizes histamine H1 receptors, reducing allergic symptoms and inducing sedation via central H1 blockade.
1 g intravenous every 6 hours.
One tablet (naproxen sodium 220 mg / diphenhydramine hydrochloride 25 mg) orally every 8 hours as needed, not to exceed 2 tablets in 24 hours.
None Documented
None Documented
Terminal elimination half-life: 12-15 hours (prolonged to 24-30 hours in moderate-to-severe renal impairment, requiring dose adjustment)
Naproxen: 12-17 hours (mean ~14 hours); clinically, allows twice-daily dosing for sustained anti-inflammatory effect. Diphenhydramine: 4-10 hours (mean ~7 hours); shorter half-life supports sedative effect for sleep induction.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Naproxen: renal excretion of naproxen and its metabolites (95% as unchanged drug and conjugated metabolites, primarily 6-O-desmethylnaproxen). Diphenhydramine: renal excretion of unchanged drug and metabolites (primarily as diphenylmethoxyacetic acid); approximately 50-60% eliminated in urine as unchanged drug and metabolites, with a small fraction in feces.
Category C
Category D/X
NSAID
NSAID